Trial Profile
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Clopidogrel
- Indications Cardiovascular disorders; Myocardial infarction; Peripheral arterial disorders; Stroke
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EUCLID
- Sponsors AstraZeneca
- 01 Feb 2022 Results of a post hoc analysis assessed the world regional differences in outcomes published in the Vascular Medicine
- 01 Feb 2022 Results published in the Journal of Vascular Surgery
- 18 Feb 2020 Results of post-hoc analysis were published in the Journal of the American College of Cardiology